Feature Channels: Heart Disease

• share
• favorite_border

Research may lead to identifying novel therapies for cardiac patients

• share
• favorite_border

Do people with COVID-19 run a risk of developing myocarditis? Cardiologist Dr. John Boehmer examines the latest research in this week’s Medical Minute.

• share
• favorite_border

Los estudios sobre una enfermedad cardíaca genética expusieron un mecanismo nuevo e inesperado de la insuficiencia cardíaca. Este descubrimiento emblemático encontró una correlación entre el agrupamiento de proteínas ligadas al ARN y los agregados de proteína existentes en tejidos cardíacos con miocardiopatía dilatada por el gen RBM20.

• share
• favorite_border

Only program in New York City to receive prestigious recognition

• share
• favorite_border

The Cardiovascular Research Foundation (CRF) has announced that the 2021 Chronic Total Occlusion (CTO) Summit will now take place as a virtual event called CTO Connect. It will take place online February 20-21, 2021. The conference will feature live case transmissions performed by some of the world’s leading operators along with real-time analysis from world-class faculty members. Live and on-demand sessions will also highlight engaging case-based discussions, challenging cases, and the latest technical developments and refinements in CTO PCI.

• share
• favorite_border

DALLAS – Nov. 17, 2020 – Research presented today by UT Southwestern cardiologists at the annual American Heart Association (AHA) Scientific Sessions 2020 showed that Black and Hispanic people were more likely to be hospitalized with COVID-19 than white patients, and that nonwhite men with cardiovascular disease or risk factors were more likely to die.

• share
• favorite_border

For many of us, this year’s holiday season may look different, and many are asking how we can enjoy the fellowship of the season while keeping ourselves, our loved ones and our communities safe from COVID-19.

• share
• favorite_border

DALLAS – Nov. 17, 2020 – Being younger doesn’t protect against the dangers of COVID-19 if you are overweight, according to a new study from UT Southwestern. While all adults who are overweight or obese are at greater risk for serious complications from the disease, the link is strongest for those age 50 and under.

• share
• favorite_border

People taking dummy pills and statins experienced similar side effects in a new study.

• share
• favorite_border

Adults with the healthiest sleep patterns had a 42% lower risk of heart failure regardless of other risk factors compared to adults with unhealthy sleep patterns, according to new research published today in the American Heart Association's flagship journal Circulation.

• share
• favorite_border

A new national policy was created to make determining who receives a heart transplant more fair. But new data shows it changed some practice patterns, too.

• share
• favorite_border

For the first time, a medication has impacted heart muscle thickness and function for patients with the most common inherited heart condition, hypertrophic cardiomyopathy, rather than simply addressing their symptoms.

• share
• favorite_border

Cleveland: Cleveland Clinic researchers have found that cryoballoon ablation as the initial treatment for atrial fibrillation is more effective than current standard-of-care management using medications. The study was published today in the New England Journal of Medicine.

• share
• favorite_border

The research team discovered it could improve irregular heart rhythms – even when the heart’s blood supply was completely shut off – by altering concentrations of common electrolytes in the bloodstream.

• share
• favorite_border

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found.

• share
• favorite_border

Cleveland: Findings from a new Cleveland Clinic study do not support the use of a high dose omega-3 fatty acid formulation to reduce major adverse cardiovascular events in patients with high cardiovascular risk. Findings from the STRENGTH Trial: Cardiovascular Outcomes With Omega-3 Carboxylic Acids (Epanova) In Patients With High Vascular Risk And Atherogenic Dyslipidemia were reported today during a Late Breaking Science session at the American Heart Association’s virtual Scientific Sessions 2020. The findings were also simultaneously published online in the Journal of the American Medical Association.

• share
• favorite_border

Mount Sinai clinical trial results could help lead to FDA approval

• share
• favorite_border

New research presented today at the American Heart Association Scientific Sessions suggests neither vitamin D nor the omega-3 fatty acids found in fish oil prevent the development of atrial fibrillation, a potentially serious heart rhythm disturbance.

• share
• favorite_border

The information came from the International Polycap Study 3 (TIPS-3) study which followed the participants an average of 4.6 years. The study of 5,714 people from nine countries, particularly India and the Philippines, looked at the polypill alone compared to a placebo; aspirin alone versus a placebo, and the polypill plus aspirin versus a double placebo. The men in the study were 50 or older and the women were 55 or older.

• share
• favorite_border

Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure. This landmark discovery found a correlation between the clumping of RNA-binding proteins ― long linked to neurodegenerative disease ― and the aggregates of protein found in the heart tissue of patients with RBM20 dilated cardiomyopathy.